A NEW weight loss jab that only needs to be taken once monthly leads to “substantial weight loss”, according to early trials.

The new weight loss drug which is set to give Ozempic and Mounjaro a run for their money, MariTide, is taken on a monthly ...

Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its ...

Shares of Amgen (AMGN) fell on Monday after announcing that its weight-loss drug will move into a phase 3 trial, with ...

Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.

Drugs such as Ozempic (a brand name for semaglutide) are showing promise for weight loss. Another medication in the same ...

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...

By Deena Beasley (Reuters) -People started on a low dose of Amgen's long-acting experimental obesity drug MariTide lost as ...

Amgen's MariTide showed strong weight loss and metabolic gains in Phase 2, with no new safety signals as Phase 3 trials begin in obesity and T2D.

Amgen's new drug MariTide shows promise in obesity treatment, with participants losing up to 16% body weight in a year with monthly shots.

A new trial has found that a weight loss drug taken monthly helps people to lose 20 percent of their body weight. Other weight loss medications such as Ozempic, Wegovy and Mounjaro have become popular ...

Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...